Europe Arthritic Therapeutic Market Size, Share & Trends Analysis Report By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others), By Product Type, By Country and Growth Forecast, 2023 - 2030
The Europe Arthritic Therapeutic Market would witness market growth of 4.8% CAGR during the forecast period (2023-2030).
The Germany market dominated the Europe Arthritic Therapeutic Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7,462.7 Million by 2030. The UK market is exhibiting a CAGR of 3.9% during (2023 - 2030). Additionally, The France market would experience a CAGR of 5.5% during (2023 - 2030).
Patient preferences, beliefs, and experiences play a significant role in shaping their adoption. Factors such as treatment efficacy, route of administration, frequency of dosing, potential side effects, and cost impact patients’ willingness to adhere to prescribed therapies. Establishing collaborative treatment plans that align with patient’s values, preferences, and lifestyle factors promotes shared decision-making between healthcare providers and patients.
Arthritic therapeutics are primarily utilized to manage the symptoms associated with arthritis, including pain, inflammation, stiffness, and swelling. Pharmacological interventions such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, analgesics, and disease-modifying antirheumatic drugs (DMARDs) help alleviate pain and reduce inflammation, improving mobility and enhancing the quality of life for patients with arthritis.
The aging population in Europe is accompanied by increased healthcare expenditure, as older adults require more medical services, treatments, and long-term care for chronic conditions, including arthritis. The aging population in Europe fuels demand for senior care services, specialized clinics, and multidisciplinary care teams focused on managing age-related health conditions, including arthritis. Thus, all these factors will uplift the regional market’s expansion in the coming years.
Based on Application, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others. Based on Product Type, the market is segmented into Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease Modified Anti-rheumatoid Drugs (DMARDs), Biologics, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- AbbVie, Inc.
- Pfizer, Inc.
- Amgen, Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Viatris, Inc.
- Bausch Health Companies, Inc.
- Sanofi S.A.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
By Application
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Osteoarthritis
- Ankylosing Spondylitis
- Others
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Disease Modified Anti-rheumatoid Drugs (DMARDs)
- Biologics
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Europe Arthritic Therapeutic Market, by Application
- 1.4.2 Europe Arthritic Therapeutic Market, by Product Type
- 1.4.3 Europe Arthritic Therapeutic Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market at a Glance
- 2.1 Key Highlights
- Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.2.3 Market Opportunities
- 3.2.4 Market Challenges
- 3.3 Porter’s Five Forces Analysis
- Chapter 4. Recent Strategies Deployed in the Arthritic Therapeutic Market
- Chapter 5. Europe Arthritic Therapeutic Market, by Application
- 5.1 Europe Rheumatoid Arthritis Market, by Country
- 5.2 Europe Psoriatic Arthritis Market, by Country
- 5.3 Europe Osteoarthritis Market, by Country
- 5.4 Europe Ankylosing Spondylitis Market, by Country
- 5.5 Europe Others Market, by Country
- Chapter 6. Europe Arthritic Therapeutic Market, by Product Type
- 6.1 Europe Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market, by Country
- 6.2 Europe Disease Modified Anti-rheumatoid Drugs (DMARDs) Market, by Country
- 6.3 Europe Biologics Market, by Country
- 6.4 Europe Others Market, by Country
- Chapter 7. Europe Arthritic Therapeutic Market, by Country
- 7.1 Germany Arthritic Therapeutic Market
- 7.1.1 Germany Arthritic Therapeutic Market, by Application
- 7.1.2 Germany Arthritic Therapeutic Market, by Product Type
- 7.2 UK Arthritic Therapeutic Market
- 7.2.1 UK Arthritic Therapeutic Market, by Application
- 7.2.2 UK Arthritic Therapeutic Market, by Product Type
- 7.3 France Arthritic Therapeutic Market
- 7.3.1 France Arthritic Therapeutic Market, by Application
- 7.3.2 France Arthritic Therapeutic Market, by Product Type
- 7.4 Russia Arthritic Therapeutic Market
- 7.4.1 Russia Arthritic Therapeutic Market, by Application
- 7.4.2 Russia Arthritic Therapeutic Market, by Product Type
- 7.5 Spain Arthritic Therapeutic Market
- 7.5.1 Spain Arthritic Therapeutic Market, by Application
- 7.5.2 Spain Arthritic Therapeutic Market, by Product Type
- 7.6 Italy Arthritic Therapeutic Market
- 7.6.1 Italy Arthritic Therapeutic Market, by Application
- 7.6.2 Italy Arthritic Therapeutic Market, by Product Type
- 7.7 Rest of Europe Arthritic Therapeutic Market
- 7.7.1 Rest of Europe Arthritic Therapeutic Market, by Application
- 7.7.2 Rest of Europe Arthritic Therapeutic Market, by Product Type
- Chapter 8. Company Profiles
- 8.1 AbbVie, Inc.
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Regional Analysis
- 8.1.4 Research & Development Expense
- 8.1.5 SWOT Analysis
- 8.2 Pfizer, Inc.
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional & Segmental Analysis
- 8.2.4 Research & Development Expense
- 8.2.5 Recent strategies and developments:
- 8.2.5.1 Acquisition and Mergers:
- 8.2.6 SWOT Analysis
- 8.3 Amgen, Inc.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional Analysis
- 8.3.4 Research & Development Expenses
- 8.3.5 Recent strategies and developments:
- 8.3.5.1 Acquisition and Mergers:
- 8.3.6 SWOT Analysis
- 8.4 Novartis AG
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Segmental and Regional Analysis
- 8.4.4 Research & Development Expense
- 8.4.5 Recent strategies and developments:
- 8.4.5.1 Trials and Approvals:
- 8.4.6 SWOT Analysis
- 8.5 F. Hoffmann-La Roche Ltd.
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Segmental and Regional Analysis
- 8.5.4 Research & Development Expense
- 8.5.5 SWOT Analysis
- 8.6 Viatris, Inc.
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Segmental Analysis
- 8.6.4 Research & Development Expense
- 8.6.5 Recent strategies and developments:
- 8.6.5.1 Trials and Approvals:
- 8.6.6 SWOT Analysis
- 8.7 Bausch Health Companies, Inc
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Segmental and Regional Analysis
- 8.7.4 Research & Development Expense
- 8.7.5 SWOT Analysis
- 8.8 Sanofi S.A.
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Segmental and Regional Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 Recent strategies and developments:
- 8.8.5.1 Partnerships, Collaborations, and Agreements:
- 8.8.6 SWOT Analysis
- 8.9 Merck & Co., Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Segmental and Regional Analysis
- 8.9.4 Research & Development Expenses
- 8.9.5 Recent strategies and developments:
- 8.9.5.1 Partnerships, Collaborations, and Agreements:
- 8.9.6 SWOT Analysis
- 8.10. Bristol-Myers Squibb Company
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Regional Analysis
- 8.10.4 Research & Development Expenses
- 8.10.5 SWOT Analysis
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook